Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's ...

Pfizer (PFE) stock in focus as the company sells its entire 7.3% stake in Haleon (HLN) for $3.24B. Read more here.

Pfizer Inc. (PFE) agreed to sell its remaining stake worth $3.3 billion in Haleon PLC (HLN), marking its exit from the UK-based consumer ...

Pfizer Inc. raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon Plc, culminating ...

With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. | After charting similar moves ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Pfizer sold its entire 7.3% shareholding in London-listed consumer-health company Haleon for a net sum of 2.5 billion pounds ($3.25 billion). Pfizer sold 618 million shares for 385 pence each. The ...

In a report released yesterday, Vamil Divan from Guggenheim maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Pfizer still owns about 7.3% of the company making it the largest shareholder. GSK sold its remaining stake in May last year.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Summit Therapeutics (NASDAQ: SMMT) was one of the stars of the biotech industry. Summit's market capitalization of $15.3 billion is exceedingly rare among clinical-stage drugmakers, signaling the ...

Meanwhile, fellow Swiss company Novartis will no longer use diverse panels in its hiring process for U.S.-based employees, ...